Skip to content

Semantic Recognition Task (SRT) in Alzheimer Disease

A Sensitive Measurement Proposal in Alzheimer's Disease: Semantic Recognition Task

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05711888
Acronym
SRT
Enrollment
80
Registered
2023-02-03
Start date
2022-12-21
Completion date
2027-12-26
Last updated
2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

Alzheimer Disease, Recognition, Semantic, Memory, Free and Cued Selective Reminding Test

Brief summary

The goal of this study is to observe the outcomes of a semantic recognition task in Alzheimer Disease and discuss what this might add to clinical practice.

Detailed description

In classical memory testing procedures, the outcomes of recognition task is related to hippocampal memory deficits knowing that the recognition task is not purely temporal lobe activity. The aim of this study is to propose a recognition task more specific to temporal lobe activity.

Interventions

BEHAVIORALSemantic Recognition Procedure

A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.

Sponsors

Istanbul University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Semantic recognition task outcomes are observed in people diagnosed with Alzheimer's disease with Non-Alzheimer population.

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* to have biomarker analysis for Alzheimer disease (positive or negative).

Exclusion criteria

* illiteracy

Design outcomes

Primary

MeasureTime frameDescription
Semantic Recognition Task1 dayThe number of correct answers will be observed just after the short-term learning procedure and just after the delayed recall procedure among people with positive biomarker compared to those with negative biomarker to Alzheimer Disease.

Countries

Turkey (Türkiye)

Contacts

Primary ContactJbid Dursun Uncu, Psy. M.
jbiddursun@gmail.com+905339390273

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026